Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma.
Adenocarcinoma
/ blood
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers
Clinical Decision-Making
Combined Modality Therapy
Comorbidity
Cytokines
/ blood
Decision Trees
Disease Management
Female
Humans
Inflammation Mediators
/ blood
Male
Middle Aged
Neoadjuvant Therapy
Pancreatic Neoplasms
/ blood
Prognosis
Retrospective Studies
Treatment Outcome
Journal
Journal of immunotherapy (Hagerstown, Md. : 1997)
ISSN: 1537-4513
Titre abrégé: J Immunother
Pays: United States
ID NLM: 9706083
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
11
09
2020
accepted:
12
02
2021
pubmed:
4
5
2021
medline:
18
1
2022
entrez:
3
5
2021
Statut:
ppublish
Résumé
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles to significant response to NAT. PDAC patients receiving NAT were classified as responders (R) or nonresponders (NR) by carbohydrate antigen 19-9 response, pathologic tumor size, and lymph node status in the resected specimen. Baseline (treatment-naive) plasma was analyzed to determine levels of 27 inflammatory mediators. Logistic regression was used to correlate individual mediators with response. Network analysis and Pearson correlation maps were derived to determine baseline inflammatory mediator profiles. Forty patients (20R and 20NR) met study criteria. The R showed significantly higher overall survival (59.4 vs. 21.25 mo, P=0.002) and disease-free survival (50.97 vs. 10.60 mo, P=0.005), compared with NR. soluble interleukin-2 receptor alpha was a significant predictor of no response to NAT (P=0.045). Analysis of inflammatory profiles using the Pearson heat map analysis followed by network analysis depicted increased inflammatory network complexity in NR compared with R (1.69 vs. 1), signifying a more robust baseline inflammatory status of NR. A panel of inflammatory mediators identified by logistic regression and Fischer score analysis was used to create a potential decision tree to predict NAT response. We demonstrate that baseline inflammatory profiles are associated with response to NAT in PDAC, and that an upregulated inflammatory status is associated with a poor response to NAT. Further analysis into the role of inflammatory mediators as predictors of chemotherapy response is warranted.
Identifiants
pubmed: 33935273
doi: 10.1097/CJI.0000000000000370
pii: 00002371-202106000-00002
pmc: PMC8102434
mid: NIHMS1687771
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-192Subventions
Organisme : NCI NIH HHS
ID : U01 CA152653
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA200466
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. 2019. Based on November 2018 SEER data submission, posted to the SEER web site. Available at: https://seer.cancer.gov/csr/1975_2016/ . Accessed October 14, 2020.
Schorn S, Demir IE, Reyes CM, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma—a systematic review and meta-analysis. Cancer Treat Rev. 2017;55:96–106.
Zhan HX, Xu JW, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6:1201–1219.
Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg. 2019;270:400–413.
Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156:108.e1–118.e4.
Al Abbas AI, Zenati M, Reiser CJ, et al. Serum CA19-9 response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma. Ann Surg Oncol. 2020;27:2007–2014.
Swidnicka-Siergiejko AK, Gomez-Chou SB, Cruz-Monserrate Z, et al. Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Oncogene. 2017;36:3149–3158.
Ahn KS, Hwang JY, Han HS, et al. The impact of acute inflammation on progression and metastasis in pancreatic cancer animal model. Surg Oncol. 2018;27:61–69.
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–444.
Murthy P, Zenati MS, Al Abbas AI, et al. Prognostic Value of the Systemic Immune-Inflammation Index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27:898–906.
Nielsen MF, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol. 2016;22:2678–2700.
Hamada S, Masamune A, Shimosegawa T. Inflammation and pancreatic cancer: Disease promoter and new therapeutic target. J Gastroenterol. 2014;49:605–617.
Dallal RM, Christakos P, Lee K, et al. Paucity of dendritic cells in pancreatic cancer. Surgery. 2002;131:135–138.
Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science. 2009;324:1400–1401.
Usul Afsar Ç, Karabulut M, Karabulut S, et al. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. J Infect Chemother. 2017;23:196–200.
Shi Y, Gao W, Lytle NK, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019;569:131–135.
Kakar S, Shi C, Adsay V, et al. Protocol for the Examination of Specimens From Patients With Carcinoma of the Pancreas, version Pancreas Exocrine 4.0.0.1. CAP, 2017. Available at: https://documents.cap.org/protocols/cp-gihepatobiliary-pancreas-exocrine17protocol4001.pdf . Accessed October 14, 2020.
Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–1339.
Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20:6212–6222.
Li J, Cheng K, Wang S, et al. Feature selection. ACM Computing Surveys. 2017;50:1–45.
Vodovotz Y, Simmons RL, Gandhi CR, et al. “Thinking” vs. “talking”: Differential autocrine inflammatory networks in isolated primary hepatic stellate cells and hepatocytes under hypoxic stress. Front Physiol. 2017;8:1104.
Sachdev U, Vodovotz L, Bitner J, et al. Suppressed networks of inflammatory mediators characterize chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2018;6:358–366.
Zamora R, Vodovotz Y, Mi Q, et al. Data-driven modeling for precision medicine in pediatric acute liver failure. Mol Med. 2017;22:821–829.
Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416.
Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. 2018;281:57–61.
Yazawa T, Shibata M, Gonda K, et al. Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol. 2013;1:675–679.
Wu HH, Hwang-Verslues WW, Lee WH, et al. Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med. 2015;212:333–349.
Gong Z, Ma J, Su H, et al. Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer. Int J Clin Oncol. 2018;23:659–670.
Zhuang Z, Ju HQ, Aguilar M, et al. IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-κB activation. Clin Cancer Res. 2016;22:1432–1444.
Zhang D, Li L, Jiang H, et al. Tumor-stroma IL1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res. 2018;78:1700–1712.
Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23:598–604.
Berglund LJ, Avery DT, Ma CS, et al. IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood. 2013;122:3940–3950.
Vang KB, Yang J, Mahmud SA, et al. IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol. 2008;181:3285–3290.
Heninger AK, Theil A, Wilhelm C, et al. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J Immunol. 2012;189:5649–5658.
Shi LZ, Fu T, Guan B, et al. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun. 2016;7:12335.
Mohammed S, Sukumaran S, Bajgain P, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25:249–258.
Zhang M, Ding G, Zhou L, et al. Interferon gamma inhibits CXCL8-induced proliferation and migration of pancreatic cancer BxPC-3 cell line via a RhoGDI2/Rac1/NF-κB signaling pathway. J Interferon Cytokine Res. 2018;38:413–422.
Zhao J, Xiao Z, Li T, et al. Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer. ACS Nano. 2018;12:9881–9893.
Farajzadeh Valilou S, Keshavarz-Fathi M, Silvestris N, et al. The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine Growth Factor Rev. 2018;39:46–61.
Helm O, Held-Feindt J, Grage-Griebenow E, et al. Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. Int J Cancer. 2014;135:843–861.
Price-Troska T, Yang ZZ, Diller D, et al. Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. Invest New Drugs. 2019;37:9–16.
Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 2014;25:415–421.
Pop VV, Seicean A, Lupan I, et al. IL-6 roles—molecular pathway and clinical implication in pancreatic cancer—a systemic review. Immunol Lett. 2017;181:45–50.
St Paul M, Saibil SD, Lien SC, et al. IL6 Induces an IL22+ CD8+ T-cell subset with potent antitumor function. Cancer Immunol Res. 2020;8:321–333.
Imafuji H, Matsuo Y, Ueda G, et al. Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL8 production in pancreatic cancer. Oncol Rep. 2019;41:3508–3516.